TP53 and non-small cell lung carcinoma: We used H460 cells from a KRASQ61H-mutant, p53 wild-type non-small cell lung cancer (NSCLC) patient, adapted the parental H460 (H460par) cells by dose escalation to CDDP, a standard component of first-line chemotherapy for NSCLC, and obtained CDDP-resistant H460res cells19,32.